Clinical and Experimental Hypertension (New York, N.y. : 1993)最新文献_第5页

Characteristics of patients with severe heart failure exhibiting exercise oscillatory ventilation. 表现出运动振荡通气的严重心力衰竭患者的特征。

IF 12.3

Clinical and Experimental Hypertension (New York, N.y. : 1993) Pub Date : 2013-01-01 Epub Date: 2013-03-28 DOI: 10.3109/10641963.2013.780071

Ryosuke Matsuki, Tomohiko Kisaka, Ryoji Ozono, Hiroki Kinoshita, Yoshiharu Sada, Noboru Oda, Takayuki Hidaka, Naonori Tashiro, Makoto Takahashi, Kiyokazu Sekikawa, Yoshihiro Ito, Hiroaki Kimura, Hironobu Hamada, Yasuki Kihara

{"title":"Characteristics of patients with severe heart failure exhibiting exercise oscillatory ventilation.","authors":"Ryosuke Matsuki, Tomohiko Kisaka, Ryoji Ozono, Hiroki Kinoshita, Yoshiharu Sada, Noboru Oda, Takayuki Hidaka, Naonori Tashiro, Makoto Takahashi, Kiyokazu Sekikawa, Yoshihiro Ito, Hiroaki Kimura, Hironobu Hamada, Yasuki Kihara","doi":"10.3109/10641963.2013.780071","DOIUrl":"https://doi.org/10.3109/10641963.2013.780071","url":null,"abstract":"This study aims to elucidate the characteristics of patients with severe nonischemic heart failure exhibiting exercise oscillatory ventilation (EOV) and the association of these characteristics with the subjective dyspnea. Forty-six patients with nonischemic heart failure who were classified into the New York Heart Association (NYHA) functional class III underwent cardiopulmonary exercise testing (CPX) and were divided into two groups according to the presence or absence of EOV. We evaluated the patients by using the Specific Activity Scale (SAS), biochemical examination, echocardiographic evaluation, results of CPX and symptoms during CPX (Borg scale), and reasons for exercise termination. EOV was observed in 20 of 46 patients. The following characteristics were observed in patients with EOV as compared with those without EOV with statistically significant differences: more patients complaining dyspnea as the reason for exercise termination, lower SAS score, higher N-terminal pro-brain natriuretic peptide level, larger left atrial dimension and volume, left ventricular end-diastolic volume, higher Borg scale score at rest and at the anerobic threshold, higher respiratory rate at rest and at peak exercise, and higher slope of the minute ventilation-to-CO₂ output ratio, and lower end-tidal CO₂ pressure at peak exercise. Among the subjects with NYHA III nonischemic heart failure, more patients with EOV had a stronger feeling of dyspnea during exercise as compared with those without EOV, and the subjective dyspnea was an exercise-limiting factor in many cases.","PeriodicalId":286988,"journal":{"name":"Clinical and Experimental Hypertension (New York, N.y. : 1993)","volume":" ","pages":"267-72"},"PeriodicalIF":12.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/10641963.2013.780071","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40230149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13

Aliskiren reduces morning blood pressure in hypertensive patients with diabetic nephropathy on hemodialysis. Aliskiren降低高血压合并糖尿病肾病血液透析患者的晨血压。

IF 12.3

Clinical and Experimental Hypertension (New York, N.y. : 1993) Pub Date : 2013-01-01 Epub Date: 2013-03-27 DOI: 10.3109/10641963.2013.780066

Tsuneo Takenaka, Mika Okayama, Eriko Kojima, Yuka Nodaira, Jonde Arai, Kosuke Uchida, Tomohiro Kikuta, Keita Sueyoshi, Hitoshi Hoshi, Yusuke Watanabe, Hiroshi Takane, Hiromichi Suzuki

{"title":"Aliskiren reduces morning blood pressure in hypertensive patients with diabetic nephropathy on hemodialysis.","authors":"Tsuneo Takenaka, Mika Okayama, Eriko Kojima, Yuka Nodaira, Jonde Arai, Kosuke Uchida, Tomohiro Kikuta, Keita Sueyoshi, Hitoshi Hoshi, Yusuke Watanabe, Hiroshi Takane, Hiromichi Suzuki","doi":"10.3109/10641963.2013.780066","DOIUrl":"https://doi.org/10.3109/10641963.2013.780066","url":null,"abstract":"Our previous study indicated that the exchange from an angiotensin receptor blocker (ARB) to aliskiren reduced morning blood pressure and albuminuria in hypertensive patients with diabetic nephropathy. We extended the above study and assessed the effects of exchanging from an ARB to aliskiren on home blood pressure in hypertensive patients with diabetic nephropathy on chronic hemodialysis. The patients who were persistently hypertensive despite antihypertensive therapy, including ARB, were considered as candidates for the exchange from the ARB to aliskiren. Patients' age and durations of diabetes and hemodialysis were averaged as 62 ± 9 years old, 15 ± 8 and 7 ± 3 years, respectively. Aliskiren decreased morning systolic blood pressure (149 ± 14 to 144 ± 13 mm Hg, n = 30, P < .01) and plasma renin activity (3.5 ± 1.1 to 1.2 ± 0.6 ng/mL/h, P < .01) without changes in serum potassium. Aliskiren also reduced interdialytic weight gain (2.7 ± 0.6 to 2.5 ± 0.5 kg/interval, P < .05) and attenuated the magnitude of intradialytic declines in systolic (-20 ± 11 to -17 ± 10 mm Hg, P < .05) and diastolic blood pressure (-9 ± 6 to -5 ± 5 mm Hg, P < .01). The exchange from an ARB to aliskiren is safe and useful to control home blood pressure in hypertensive hemodialysis patients with diabetic nephropathy. Aliskiren reduced both intradialytic blood pressure drops and interdialytic weight gain in patients with DN.","PeriodicalId":286988,"journal":{"name":"Clinical and Experimental Hypertension (New York, N.y. : 1993)","volume":" ","pages":"244-9"},"PeriodicalIF":12.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/10641963.2013.780066","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40229539","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Toward a personalized chronotherapy of high blood pressure and a circadian overswing. 迈向个体化高血压时间疗法和昼夜节律紊乱。

IF 12.3

Clinical and Experimental Hypertension (New York, N.y. : 1993) Pub Date : 2013-01-01 Epub Date: 2013-03-29 DOI: 10.3109/10641963.2013.780073

Yoshihiko Watanabe, Franz Halberg, Kuniaki Otsuka, Germaine Cornelissen

{"title":"Toward a personalized chronotherapy of high blood pressure and a circadian overswing.","authors":"Yoshihiko Watanabe, Franz Halberg, Kuniaki Otsuka, Germaine Cornelissen","doi":"10.3109/10641963.2013.780073","DOIUrl":"https://doi.org/10.3109/10641963.2013.780073","url":null,"abstract":"Timing can greatly affect the response to a stimulus, including antihypertensive medications. Herein, we assess the response of 30 patients to losartan/hydrochlorothiazide (L/H), administered for at least 1 month at a given circadian stage to each patient, this stage being changed during consecutive spans to cover six treatment times from awakening to bedtime at approximately 3-hour intervals. At the end of each stage, each patient underwent a 7-day around-the-clock ambulatory blood pressure (BP) profile, analyzed chronobiologically. A larger reduction of the midline estimating statistic of rhythm (MESOR; a rhythm-adjusted mean) of diastolic BP was achieved by L/H administration in the early morning for more patients (P < .05), while treatment upon awakening was the best choice for most patients to reduce the circadian amplitude of BP the most (P < .01). The optimal treatment time varied considerably among patients, however. Special attention should be given to the effect on the circadian amplitude since treatment can increase it above a threshold, beyond which there is a marked increase in cardiovascular disease risk. The results indicate the desirability to individualize the optimization of the antihypertensive effect of L/H by timing along the circadian scale.","PeriodicalId":286988,"journal":{"name":"Clinical and Experimental Hypertension (New York, N.y. : 1993)","volume":" ","pages":"257-66"},"PeriodicalIF":12.3,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/10641963.2013.780073","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40235054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 23

The incidence of intraoperative hypertension and risk factors for its development during thyroid surgery. 甲状腺手术中术中高血压的发生率及其发展的危险因素。

IF 12.3

Clinical and Experimental Hypertension (New York, N.y. : 1993) Pub Date : 2013-01-01 Epub Date: 2013-01-09 DOI: 10.3109/10641963.2012.758735

Nevena Kalezic, Marina Stojanovic, Biljana Milicic, Vesna Antonijevic, Vera Sabljak, Dejan Markovic, Vladan Zivaljevic

引用次数: 4

Three-year safety and effectiveness of fixed-dose losartan/hydrochlorothiazide combination therapy in Japanese patients with hypertension under clinical setting (PALM-1 Extension Study). 在临床环境下，固定剂量氯沙坦/氢氯噻嗪联合治疗日本高血压患者三年的安全性和有效性(PALM-1扩展研究)。

IF 12.3

Clinical and Experimental Hypertension (New York, N.y. : 1993) Pub Date : 2012-01-01 Epub Date: 2012-04-25 DOI: 10.3109/10641963.2012.666606

Toshihiro Kita, Naoto Yokota, Yoshinari Ichiki, Takao Ayabe, Takuma Etoh, Noboru Tamaki, Johji Kato, Tanenao Eto, Kazuo Kitamura

引用次数: 4

Trend of blood pressure control status in hypertensive outpatients: with special reference to elderly hypertensives. 高血压门诊患者血压控制状况变化趋势:特别针对老年高血压患者。

IF 12.3

Clinical and Experimental Hypertension (New York, N.y. : 1993) Pub Date : 2012-01-01 Epub Date: 2012-05-01 DOI: 10.3109/10641963.2012.681224

Yuko Ohta, Takuya Tsuchihashi, Kanako Kiyohara, Hideyuki Oniki

{"title":"Trend of blood pressure control status in hypertensive outpatients: with special reference to elderly hypertensives.","authors":"Yuko Ohta, Takuya Tsuchihashi, Kanako Kiyohara, Hideyuki Oniki","doi":"10.3109/10641963.2012.681224","DOIUrl":"https://doi.org/10.3109/10641963.2012.681224","url":null,"abstract":"Blood pressure (BP) control in hypertensives has improved; however, it still remains to be insufficient. We have investigated the trend in BP control status of the hypertensive patients followed for 10 years in hypertension clinic. Subjects included 133 patients who have been followed from the first visit during 1998-2000 to the last visit during 2008-2010. During the mean follow-up period of 10.5 years, average BP and body weight significantly (P < .01) decreased from 143 ± 12/85 ± 8 mm Hg to 129 ± 14/68 ± 11 mm Hg, and from 59.8 ± 9.9 kg to 58.7 ± 10.6 kg, respectively. The achievement rate of good BP control defined as <140/90 mm Hg and the number of antihypertensive drugs also increased significantly during this period (39.1%-77.5% and 1.3 ± 1.0-2.2 ± 1.1, respectively, P < .01). Blood pressure control improved and the number of antihypertensive drugs also increased in 45 patients who were older than 65 years at the last visit. The use of Ca channel blockers (CCBs), angiotensin II receptor antagonists, and diuretics increased significantly during this period. Results suggest that lifestyle modification including body weight reduction as well as intensive antihypertensive treatment contributed to the improved BP control in hypertensive patients including the elderly.","PeriodicalId":286988,"journal":{"name":"Clinical and Experimental Hypertension (New York, N.y. : 1993)","volume":" ","pages":"258-63"},"PeriodicalIF":12.3,"publicationDate":"2012-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/10641963.2012.681224","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40194392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

A bedtime dose of ARB was better than a morning dose in improving baroreflex sensitivity and urinary albumin excretion--the J-TOP study. J-TOP研究表明，睡前服用ARB比早晨服用ARB更能改善压力反射敏感性和尿白蛋白排泄。

IF 12.3

Clinical and Experimental Hypertension (New York, N.y. : 1993) Pub Date : 2012-01-01 Epub Date: 2012-04-25 DOI: 10.3109/10641963.2012.666604

Kazuo Eguchi, Motohiro Shimizu, Satoshi Hoshide, Kazuyuki Shimada, Kazuomi Kario

引用次数: 21

Inhibitory effect of aqueous and ethanolic garlic (Allium sativum L., Lilliaceae) extracts on the rat atria. 大蒜(Allium sativum L.， Lilliaceae)提取物对大鼠心房的抑制作用。

IF 12.3

Clinical and Experimental Hypertension (New York, N.y. : 1993) Pub Date : 2010-01-01 DOI: 10.3109/10641960903265238

Mirjana Radenkovic, Suzana Brankovic, Dusanka Kitic, Slavimir Veljkovic, Vesna Ivetic, Milkica Nesić, Bojana Miladinovic

{"title":"Inhibitory effect of aqueous and ethanolic garlic (Allium sativum L., Lilliaceae) extracts on the rat atria.","authors":"Mirjana Radenkovic, Suzana Brankovic, Dusanka Kitic, Slavimir Veljkovic, Vesna Ivetic, Milkica Nesić, Bojana Miladinovic","doi":"10.3109/10641960903265238","DOIUrl":"https://doi.org/10.3109/10641960903265238","url":null,"abstract":"The acute negative inotropic and chronotrophic effects of aqueous and alcoholic garlic extracts (Allium sativum L.) on spontaneous and adrenalin-stimulated contractions of the Wistar rat atria were investigated. The addition of garlic extracts to isolated rat atria evoked negative inotropic and chronotropic effects. Ethanolic garlic extract exerts much stronger negative inotropic (58.33 +/- 14.76%) effects than aqueous extract (43.66 +/- 16.32%). The difference in frequency reduction is especially conspicuous. Aqueous garlic extract very slightly affects the frequency, while ethanolic extract reduces it by more than 40%. In addition to these effects, the positive inotropism and chronotropism induced by the addition of noradrenaline, were much more antagonized by ethanolic garlic extract than by aqueous extract. Moreover, ethanolic garlic extract establishes sinus rhythm in the atria with extrasystoles induced by noradrenaline.","PeriodicalId":286988,"journal":{"name":"Clinical and Experimental Hypertension (New York, N.y. : 1993)","volume":" ","pages":"251-5"},"PeriodicalIF":12.3,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/10641960903265238","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29149322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo. 人体内嗜铬粒蛋白A （CHGA）肽catestatin的直接血管活性作用。

Clinical and Experimental Hypertension (New York, N.y. : 1993) Pub Date : 2010-01-01 DOI: 10.3109/10641960903265246

Maple M Fung, Rany M Salem, Parag Mehtani, Brenda Thomas, Christine F Lu, Brandon Perez, Fangwen Rao, Mats Stridsberg, Michael G Ziegler, Sushil K Mahata, Daniel T O'Connor

{"title":"Direct vasoactive effects of the chromogranin A (CHGA) peptide catestatin in humans in vivo.","authors":"Maple M Fung, Rany M Salem, Parag Mehtani, Brenda Thomas, Christine F Lu, Brandon Perez, Fangwen Rao, Mats Stridsberg, Michael G Ziegler, Sushil K Mahata, Daniel T O'Connor","doi":"10.3109/10641960903265246","DOIUrl":"10.3109/10641960903265246","url":null,"abstract":"Catestatin is a bioactive peptide of chromogranin A (CHGA) that is co-released with catecholamines from secretory vesicles. Catestatin may function as a vasodilator and is diminished in hypertension. To evaluate this potential vasodilator in vivo without systemic counterregulation, we infused catestatin to target concentrations of approximately 50, approximately 500, approximately 5000 nM into dorsal hand veins of 18 normotensive men and women, after pharmacologic venoconstriction with phenylephrine. Pancreastatin, another CHGA peptide, was infused as a negative control. After preconstriction to approximately 69%, increasing concentrations of catestatin resulted in dose-dependent vasodilation (P = 0.019), in female subjects (to approximately 44%) predominantly. The EC(50) (approximately 30 nM) for vasodilation induced by catestatin was the same order of magnitude to circulating endogenous catestatin (4.4 nM). No vasodilation occurred during the control infusion with pancreastatin. Plasma CHGA, catestatin, and CHGA-to-catestatin processing were then determined in 622 healthy subjects without hypertension. Female subjects had higher plasma catestatin levels than males (P = 0.001), yet lower CHGA precursor concentrations (P = 0.006), reflecting increased processing of CHGA-to-catestatin (P < 0.001). Our results demonstrate that catestatin dilates human blood vessels in vivo, especially in females. Catestatin may contribute to sex differences in endogenous vascular tone, thereby influencing the complex predisposition to hypertension.","PeriodicalId":286988,"journal":{"name":"Clinical and Experimental Hypertension (New York, N.y. : 1993)","volume":" ","pages":"278-87"},"PeriodicalIF":0.0,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3109075/pdf/nihms296615.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29148697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Time to achieve blood pressure goal with a combination versus a conventional monotherapy approach in hypertensive patients with metabolic syndrome. 代谢综合征高血压患者联合治疗与传统单药治疗达到血压目标的时间

IF 12.3

Clinical and Experimental Hypertension (New York, N.y. : 1993) Pub Date : 2010-01-01 DOI: 10.3109/10641960903265212

Roberto Fogari, Annalisa Zoppi, Ilaria Ferrari, Amedeo Mugellini, Paola Preti, Giuseppe Derosa

{"title":"Time to achieve blood pressure goal with a combination versus a conventional monotherapy approach in hypertensive patients with metabolic syndrome.","authors":"Roberto Fogari, Annalisa Zoppi, Ilaria Ferrari, Amedeo Mugellini, Paola Preti, Giuseppe Derosa","doi":"10.3109/10641960903265212","DOIUrl":"https://doi.org/10.3109/10641960903265212","url":null,"abstract":"The time to achieve a blood pressure (BP) goal < or =130/85 mmHg with a combination versus a conventional monotherapy approach was evaluated in 308 hypertensive patients with metabolic syndrome. They were randomized to valsartan (V) 8 mg/amlodipine (A) 5 mg combination or to V 160 mg monotherapy for 12 weeks and every 2 weeks, there was a titration in nonresponder patients: in the combination group V/A was progressively increased to V 160/A 5 mg; V160/A 7.5 mg; V160/A 10 mg; V 240/A 10 mg, and V 320/A 10 mg. In the monotherapy group, the regimen was progressively modified as following: V 240 mg; V 320 mg; V 320/A 5 mg; V 320/A 7.5 mg, and V 320/A 10 mg. The mean time to achieve the BP goal was shorter in patients randomized to combination therapy compared to those randomized to conventional monotherapy (4.7 +/- 2.7 weeks vs. 7.1 +/- 3.9 weeks, respectively, p < 0.001). The percentage of patients who achieved target BP in the combination approach group statistically exceeded that of the monotherapy treated one already after 2 weeks of treatment (30.5 vs. 14.9%, p < 0.01) and again after 4, 6, 8, and 10 weeks of treatment. Only at 12 weeks the percentage of normalized patients was similar in the two treatment groups (78.8% vs. 75.3%, ns). These results suggest that initial therapy with a V/A combination approach may be more quickly effective than a conventional sequential monotherapy approach in achieving target BP in hypertensive patients with metabolic syndrome.","PeriodicalId":286988,"journal":{"name":"Clinical and Experimental Hypertension (New York, N.y. : 1993)","volume":" ","pages":"245-50"},"PeriodicalIF":12.3,"publicationDate":"2010-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3109/10641960903265212","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"29149321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10